Code intelligence

FDA-NDA201743 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-NDA201743.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated

Critical

High

100%

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: ARGATROBAN IN DEXTROSE (ARGATROBAN) — Type 5 - New Formulation or New Manufacturer

Policy FDA-NDA201743 · Hematology

High

Argatroban in dextrose is an injectable medication that is likely to receive a J-code assignment for Medicare billing. Since it falls under Part B, billing may involve ASP+6% reimbursement if it meets

View alert